All In Biotech

Drug Trial Radar · NCT06224673

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Nov 30, 2029

Study completion Nov 30, 2029

Sponsor

Lead sponsor
Laura Huppert, MD, BAAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ambrx, Inc.
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.

Conditions

  • HER2 Low Breast Carcinoma
  • Triple Negative Breast Cancer
  • Hormone-receptor-positive Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma

Interventions

  • ARX788Drug

    Given IV

  • Computed Tomography (CT)Procedure

    Undergo CT or Positron Emission Tomography(PET)/CT

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • AmilorideDrug

    Ophthalmologic drops given topically to participants for an eye toxicity substudy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.